Our study forecasts sales of 25 marketed products, including these brands: -- Claritin/ Claritin OTC -- Allegra/ Allegra-D/ Allegra OTC -- Staloral -- Ragwitek -- Nasonex -- Omnaris -- Patanase -- Astepro
A handful of products have received new product approvals in Europe, such as Zyclara, Astepro
, Onsolis and Edluar.
Our study forecasts sales of 26 products, including these brands: -- Nasonex -- Allegra/Allegra-D/Allegra OTC -- Zyrtec/Zyrtec D -- Claritin/Claritin OTC -- Astepro
-- Avamys/Veramyst -- Xyzal -- Allelock -- Staloral -- Clarinex Discover how high revenues can go.
(once-daily azelastine; Meda Pharma): head-to-head trials lead to a successful switch
sales are increasing slightly, which is important to the launch of Dymista, our most important new product, which is being introduced in the US in the fall and provides a basis for strong growth.
is a new nasal spray for the treatment of allergic rhinitis.
3 million under the Company's agreement with Perrigo Company, plc related to the launch of generic Astepro
, as well as higher profit share earned under the Company's agreement with Teva Pharmaceutical Industries, Limited of $2.
In addition, Astepro
(azelastine hydrochloride), Xyzal (levocetirizine) and Singulair (montelukast sodium) are set to loose their patent protection in the year 2012.
According to Perrigo, Astepro
Nasal Spray is a prescription medicine for people aged 12 years and above and is approved to treat nasal symptoms caused due to seasonal allergies or environmental irritants.
The United States Patent and Trademark Office (USPTO) today issued a patent related to Astepro
(azelastine) nasal spray.
Meda will concentrate the marketing to the respiratory/allergy area with Astepro
and our new product Dymista, which is in late registration phase with the FDA.
We are also happy to report success with Astepro
, the Astelin follow-up product that now has over 50% of the total azelastine market in the US by value.